QCM Cayman’s iBio IBIO Stock Holding History

QCM Cayman’s Portfolio IBIO Stock Details IBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-40	Closed	-$31K	–	152
2021 Q1	$31K	Sell	40 -85	-68%	-$74.1K	0.09%	106
2020 Q4	$66K	Buy	125 +104	+495%	+$84.7K	0.07%	265
2020 Q3	$21K	Buy	+21	New	+$30.4K	0.04%	181

Other funds holding IBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

QCM Cayman's IBIO Position: Q2 2021 in Review

QCM Cayman sold out of iBio (IBIO) in Q2 2021, closing a stake of 40 shares — an estimated $31K sold.

QCM Cayman first reported a position in IBIO in Q3 2020 and held it in 3 quarters. The position peaked at $66K in Q4 2020. 83 funds tracked by Wall St. Rank hold IBIO as of Q2 2021.

QCM Cayman reported no remaining iBio position as of Q2 2021 after selling out during the quarter.
QCM Cayman sold 40 iBio shares in Q2 2021, an estimated $31K.
QCM Cayman first reported a position in iBio in Q3 2020 and held it in 3 quarters.
QCM Cayman's iBio position peaked at $66K in Q4 2020.
83 funds tracked by Wall St. Rank held iBio as of Q2 2021.

Based on QCM Cayman's 13F filing for Q2 2021, filed 10 Aug 2021.